Company intelligence / Profile preview

ThermoMind

Haifa, Haifa District, Israelthermomind.io ↗

Ownership: Private
Development stage: Preclinical

Overview

ThermoMind has developed a non-contact, risk-free thermal scanning device that uses high-resolution infrared sensors and advanced artificial intelligence algorithms to detect early-stage breast cancer. The technology aims to improve accuracy and comfort compared to mammography—especially for young women or those with dense breasts—and reduce false positives. A major clinical study involving up to 28,000 participants was set to begin in June 2023[5].

Therapeutic areas: Oncology
Modalities: Device
Industry: Medical Imaging

Partnerships

Eighteen global partners including leading hospitals and research institutesSCD (infrared sensor developer), a subsidiary of Elbit Systems and Rafael Advanced Defense Systems

Beyond the preview

Go deeper on ThermoMind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ThermoMind.

Explore the full profile